StevenALimentaniMD

Oncology • Charlotte, NC

Breast Cancer, Hematologic Oncology

Physician

Join to view full profile

Dr. Limentani is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Limentani's full profile

Already have an account?

Office
200 Hawthorne Ln
Fl 3
Charlotte, NC 28204
Phone(704) 384-9234
Fax(704) 417-4400
Is this information wrong?

Education & Training

Tufts Medical CenterFellowship, Medical Oncology, 1989 - 1992
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1986 - 1989
Tufts University School of MedicineClass of 1986

Certifications & Licensure

NC State Medical License 1995 - 2021
MA State Medical License 1988 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013
Charlotte Magazine Castle Connolly, 2005
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 01Brufsky, A.M.,Tolentino, A.R.,Hossain, A.M.,Lyss, A.P.,DeNittis, A.S.,Paterson, A.H.,Thomas, A.,Conlin, A.K.,Eisemann, A.D.,Zibelli, A.M.,McIntosh, A.F.,Hamad, A.,Sanyal, A.,Tiersten, A.D.,Tevaarwerk, A.J...
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy Start of enrollment: 2008 Nov 01Abraham, J.,Alden, M.,Andersen, J.C.,Anderson, N.R.,Ardman, B.,Arthur, D.W.,Atkins, J.N.,Ayers, J.D.,Aziz, S.,Baez-Diaz, L.,Baumann, J.C.,Bechar, N.,Beeker, T.A.,Behrens, R.J.,Beron, P.J.,Biggs, D.D.,Blan...

Publications & Presentations

PubMed

22 citations
Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial.
Harry D. Bear, Wen Wan, André Robidoux, Peter Rubin, Steven Limentani, Richard L. White, James Granfortuna, Judith O. Hopkins, Dwight Oldham, Angel Rodriguez, Amy P. Sing> ;Journal of Surgical Oncology. 2017 Jun 1
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a pha...
Martin M, Fumoleau P, Dewar JA, Albanell J, Limentani SA, Campone M, Chang JC, Patre M, Strasak A, de Haas SL, Xu J, Garcia-Saenz JA> ;Ann. Oncol.. 2016-07-01
12 citations
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors
Steven A. Limentani, Mario Campone, Thierry Dorval, Giuseppe Curigliano, Richard de Boer, Charles L. Vogel, Shane White, Thomas Bachelot, Jean-Luc Canon, Mary L. Disis...> ;Breast Cancer Research and Treatment. 2016 Mar 18
5 citations
Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in wome...
Jame Abraham, André Robidoux, Antoinette R. Tan, Steven A. Limentani, Keren Sturtz, Ibrahim A. Shalaby, Hope Alcorn, Marc Buyse, Norman Wolmark, Samuel A. Jacobs> ;Breast Cancer Research and Treatment. 2015 Jul 1
27 citations
Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase ...
Véronique Diéras, Hans Wildiers, Jacek Jassem, Luc Dirix, Jean-Paul Guastalla, Petri Bono, Sara A. Hurvitz, Anthony Gonçalves, Gilles Romieu, Steven A. Limentani, Guy ...> ;The Breast. 2015 Jun 1
36 citations
Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Resear...
Rachel C. Jankowitz, Jame Abraham, Antoinette R. Tan, Steven Limentani, Marni B. Tierno, Laura M Adamson, Marc Buyse, Norman Wolmark, Samuel A. Jacobs> ;Cancer Chemotherapy and Pharmacology. 2013 Sep 29
A phase I dose-escalation and pharmacokinetic (PK) evaluation of an oral AKT inhibitor, LY2503029 (LY).
Limentani SA, Burris H, Anderson AP, Brail LH, Satonin D, Gueorguieva I, Jones S, Infante JR, Bendell JC> ;J. Clin. Oncol.. 2011-05-20
A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER...
Dieras V, Jassem J, Dirix LY, Guastalla JP, Bono P, Hurvitz SA, Gonçalves A, Romieu G, Limentani SA, Jerusalem GHM, Lakshmaiah K, Roche HH, Sánchez-Rovira P, Pienkowsk...> ;J. Clin. Oncol.. 2011-05-20
330 citations
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior ...
Howard A. Burris, Hope S. Rugo, Svetislava J. Vukelja, Charles L. Vogel, Rachel A. Borson, Steven A. Limentani, Elizabeth Tan-Chiu, Ian E. Krop, Richard Alan Michaelso...> ;Journal of Clinical Oncology. 2011 Feb 1
106 citations
Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study
Joan H. Schiller, Timothy S. Larson, S.-H. Ignatius Ou, Steven A. Limentani, Alan Sandler, Everett E. Vokes, Sinil Kim, K. F. Liau, Paul Bycott, Anthony J. Olszanski, ...> ;Journal of Clinical Oncology. 2009 Aug 10
Safety and efficacy of neratinib (HKI-272) in combination with vinorelbine in patients with solid tumors.
Limentani SA, Awada A, Dirix L, Beck J, Dieras V, Binlich F, Germa C, Agrapart V, Powell C, Hershman D> ;J. Clin. Oncol.. 2009-05-20
A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results.
Vogel CL, Burris HA, Limentani S, Borson R, O'Shaughnessy J, Vukelja S, Agresta S, Klencke B, Birkner M, Rugo H> ;J. Clin. Oncol.. 2009-05-20
10 citations
Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer S...
Richard J. Gralla, Martin J. Edelman, Frank C. Detterbeck, Thierry Jahan, David M. Loesch, Steven A. Limentani, Ramaswamy Govindan, Guangbin Peng, Matthew J. Monberg, ...> ;Supportive Care in Cancer. 2009 Mar 1
61 citations
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma
Sundar Jagannath, Bart Barlogie, James R. Berenson, David S. Siegel, David Irwin, Paul G. Richardson, Ruben Niesvizky, Raymond Alexanian, Steven A. Limentani, Melissa ...> ;British Journal of Haematology. 2008 Nov 1
29 citations
Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and pacli...
Thomas E. Stinchcombe, Carrie B. Lee, Dominic T. Moore, M. Patricia Rivera, Jan Halle, Steven Limentani, Julian G. Rosenman, Mark A. Socinski> ;Journal of Thoracic Oncology. 2008 Nov 1
A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: Prelimi...
Limentani S, Just R, Purdham A, Mulay M, Bair A, Tamby JF, Chap LI, Rosen LS> ;J. Clin. Oncol.. 2008-05-20
7 citations
Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer
Frank C. Detterbeck, Mark A. Socinski, Richard J. Gralla, Martin J. Edelman, Thierry Jahan, David M. Loesch, Steven A. Limentani, Ramaswamy Govindan, M.B. Zaman, Z. Ye...> ;Journal of Thoracic Oncology. 2008 Jan 1
49 citations
Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal ...
Steven A. Limentani, Adam M. Brufsky, John K. Erban, Mohammed Jahanzeb, Deborah Lewis> ;Journal of Clinical Oncology. 2007 Apr 1
82 citations
Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung Cancer
Michael Fanucchi, Frank V. Fossella, R. J. Belt, Ronald B. Natale, Panos Fidias, David P. Carbone, Ramaswamy Govindan, Luis E. Raez, Francisco Robert, Maria H.L. Ribei...> ;Journal of Clinical Oncology. 2006 Nov 1
301 citations
Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib
Paul G. Richardson, Hannah R. Briemberg, Sundar Jagannath, Patrick Y. Wen, Bart Barlogie, James R. Berenson, Seema Singhal, David S. Siegel, David Irwin, Michael W. Sc...> ;Journal of Clinical Oncology. 2006 Jul 1
A phase 1, dose-escalation trial of STA-5312, a microtubule inhibitor with a novel binding site, in advanced or metastatic solid malignancies.
Desai A, Ratain MJ, Moshier K, Tipton M, Dooley W, Hocknell K, Dahl T, Sherman M, Limentani S> ;J. Clin. Oncol.. 2006-06-20
Safety and pharmacokinetics of intravenous VEGF Trap plus FOLFOX4 in a combination phase I clinical trial of patients with advanced solid tumors.
Mulay M, Limentani SA, Carroll M, Furfine ES, Cohen DP, Rosen LS> ;J. Clin. Oncol.. 2006-06-20
Evaluation of a recombinant HER2 vaccine: Induction of specific antibodies, T-cells and preliminary activity in metastatic breast cancer patients.
Limentani SA, Campone M, Dorval T, Tan-Chiu E, Curigliano G, De Boer R, Canon J, Bachelot T, Louahed J, Brichard VG> ;J. Clin. Oncol.. 2006-06-20
3 citations
Phase II Study of Neoadjuvant Docetaxel/Vinorelbine Followed by Surgery and Adjuvant Doxorubicin/Cyclophosphamide in Women with Stage II/III Breast Cancer
Steven A. Limentani, Affair M. Brufsky, John K. Erban, Mohammed Jahanzeb, Deborah Lewis> ;Clinical Breast Cancer. 2006 Feb 1
63 citations
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
James R. Berenson, Sundar Jagannath, Bart Barlogie, David T. Siegel, Raymond Alexanian, Paul G. Richardson, David Irwin, Melissa Alsina, S. Vincent Rajkumar, Gordon Sr...> ;Cancer. 2005 Nov 15
Join now to see all

Press Mentions

Novant Health Announces New Leader in Cancer ServicesJanuary 18th, 2017
Novant Health Rebrands Cancer Care to Show a Comprehensive Approach in a Growing SectorOctober 7th, 2020